HAPLN3 and neoplasm: In patients with de novo mPCa, we detected methylated ctDNA in 61.5% of the plasma samples and observed a positive correlation between ctDNA abundance (i.e., ratio between methylated DOCK2/HAPLN3 ctDNA and total cfDNA, respectively), Gleason Grade Group and clinical T-stage at diagnosis indicating that the level of ctDNA in de novo mPCa patients increase with increasing tumor burden.